[go: up one dir, main page]

CO2019000932A2 - Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. - Google Patents

Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.

Info

Publication number
CO2019000932A2
CO2019000932A2 CONC2019/0000932A CO2019000932A CO2019000932A2 CO 2019000932 A2 CO2019000932 A2 CO 2019000932A2 CO 2019000932 A CO2019000932 A CO 2019000932A CO 2019000932 A2 CO2019000932 A2 CO 2019000932A2
Authority
CO
Colombia
Prior art keywords
prophylaxis
derivatives
treatment
new
viral infection
Prior art date
Application number
CONC2019/0000932A
Other languages
English (en)
Inventor
Lu Gao
Xiufang Zheng
Hongying Yun
Chungen Liang
Kun Miao
Jianping Wang
Bo Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2019000932A2 publication Critical patent/CO2019000932A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I): en la que R1, R2 y R3 son tal como se indica en la presente memoria y sus profármacos o sal, enantiómero o diastereómero farmacéuticamente aceptable del mismo, y composiciones que incluyen los compuestos y métodos de utilización de los compuestos.
CONC2019/0000932A 2016-08-29 2019-01-30 Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. CO2019000932A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016097140 2016-08-29
CN2017092653 2017-07-12
PCT/EP2017/071514 WO2018041763A1 (en) 2016-08-29 2017-08-28 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
CO2019000932A2 true CO2019000932A2 (es) 2019-02-08

Family

ID=59738346

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0000932A CO2019000932A2 (es) 2016-08-29 2019-01-30 Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.

Country Status (29)

Country Link
US (3) US10233184B2 (es)
EP (2) EP3865482A1 (es)
JP (2) JP7013467B2 (es)
KR (2) KR102459155B1 (es)
CN (1) CN109641904B (es)
AU (3) AU2017320742B2 (es)
CA (1) CA3034148A1 (es)
CL (1) CL2019000512A1 (es)
CO (1) CO2019000932A2 (es)
CR (1) CR20190087A (es)
DK (1) DK3504210T3 (es)
ES (1) ES2867849T3 (es)
HR (1) HRP20210621T1 (es)
HU (1) HUE053944T2 (es)
IL (3) IL293475B2 (es)
MA (1) MA46038B1 (es)
MX (2) MX383500B (es)
MY (1) MY197408A (es)
PE (1) PE20190476A1 (es)
PH (1) PH12019500432B1 (es)
PL (1) PL3504210T3 (es)
PT (1) PT3504210T (es)
RS (1) RS61752B1 (es)
RU (1) RU2751349C2 (es)
SG (2) SG11201901633WA (es)
SI (1) SI3504210T1 (es)
TW (1) TWI671300B (es)
UA (1) UA124270C2 (es)
WO (1) WO2018041763A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045906T2 (hu) * 2015-05-08 2020-01-28 Hoffmann La Roche Új szulfonimidoilpurinon vegyületek és származékok vírusfertõzés kezelésére és megelõzésére
CR20190087A (es) * 2016-08-29 2019-04-30 Hoffmann La Roche Nuevos compuestos sulfonimidoilpurinova 7-sustituídos y derivados para el tratamiento y la profilaxis de la infección vírica
CN109715214B (zh) * 2016-09-13 2022-03-04 豪夫迈·罗氏有限公司 Tlr7激动剂和hbv衣壳组装抑制剂的组合治疗
CN111699187A (zh) 2018-02-12 2020-09-22 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的砜化合物和衍生物
PE20211456A1 (es) * 2018-02-28 2021-08-05 Hoffmann La Roche Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado
US20200113912A1 (en) 2018-09-12 2020-04-16 Silverback Therapeutics, Inc. Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途
AU2020358726A1 (en) 2019-10-01 2022-04-07 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
US20230100429A1 (en) 2020-03-02 2023-03-30 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
AU2021300362A1 (en) 2020-07-01 2023-02-23 ARS Pharmaceuticals, Inc. Anti-ASGR1 antibody conjugates and uses thereof
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
EP4194006A4 (en) 2020-08-04 2024-12-04 Progeneer Inc. mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL
CN114315861A (zh) * 2020-09-27 2022-04-12 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途
GB202306325D0 (en) 2023-04-28 2023-06-14 Iksuda Therapeutics Ltd Antibody-drug conjugate compounds, and methods of use and treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0141927B1 (en) * 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
DE69731823T2 (de) 1996-07-03 2005-12-15 Sumitomo Pharmaceuticals Co., Ltd. Neue purinderivate
AUPO912997A0 (en) 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
ES2205573T3 (es) 1997-11-28 2004-05-01 Sumitomo Pharmaceuticals Company, Limited Nuevo compuestos heterociclicos.
JPH11180981A (ja) * 1997-12-19 1999-07-06 Sumitomo Pharmaceut Co Ltd 複素環誘導体
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
CA2479037C (en) 2002-03-15 2010-11-09 Jiri Zemlicka 2-amino-9[(2-hydroxymethyl)cyclopropylidenemethyl]purines as antiviral agents
EP1550662B1 (en) * 2002-09-27 2012-07-04 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound and use thereof
KR20080006004A (ko) 2005-05-04 2008-01-15 화이자 리미티드 암 및 ｃ형 간염과 같은 바이러스 감염의 치료를 위한톨-유사 수용체 조절제인 2-아미도-6-아미노-8-옥소퓨린유도체
DE102006053049A1 (de) 2006-11-10 2008-05-15 Daimler Ag Staufach mit einer Abdeckeinrichtung
BRPI0813952A2 (pt) * 2007-06-29 2017-05-09 Gilead Sciences Inc derivados de purina e seu emprego como moduladores e receptor 7 semelhante ao dobre de sino
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
UY32306A (es) * 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
AU2010310813B2 (en) * 2009-10-22 2015-06-18 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
EP3190113B1 (en) 2014-08-15 2021-05-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyrrolopyrimidine compounds used as tlr7 agonist
HUE045906T2 (hu) * 2015-05-08 2020-01-28 Hoffmann La Roche Új szulfonimidoilpurinon vegyületek és származékok vírusfertõzés kezelésére és megelõzésére
CR20190087A (es) * 2016-08-29 2019-04-30 Hoffmann La Roche Nuevos compuestos sulfonimidoilpurinova 7-sustituídos y derivados para el tratamiento y la profilaxis de la infección vírica

Also Published As

Publication number Publication date
RU2751349C2 (ru) 2021-07-13
AU2021204303B2 (en) 2022-05-12
UA124270C2 (uk) 2021-08-18
IL284255B (en) 2022-07-01
JP2019526633A (ja) 2019-09-19
CN109641904B (zh) 2022-01-28
PE20190476A1 (es) 2019-04-04
JP7214900B2 (ja) 2023-01-30
IL264710B (en) 2021-07-29
EP3504210B1 (en) 2021-02-24
JP7013467B2 (ja) 2022-01-31
ES2867849T3 (es) 2021-10-21
EP3865482A1 (en) 2021-08-18
AU2017320742B2 (en) 2021-08-05
KR20190039829A (ko) 2019-04-15
IL293475B2 (en) 2024-10-01
AU2017320742A1 (en) 2019-02-28
US10233184B2 (en) 2019-03-19
TWI671300B (zh) 2019-09-11
RS61752B1 (sr) 2021-05-31
IL293475A (en) 2022-08-01
MX2021006902A (es) 2021-07-07
US20200385387A1 (en) 2020-12-10
CN109641904A (zh) 2019-04-16
US20180072730A1 (en) 2018-03-15
AU2022204697A1 (en) 2022-07-21
PH12019500432A1 (en) 2019-10-21
NZ750604A (en) 2024-02-23
US20190256515A1 (en) 2019-08-22
EP3504210A1 (en) 2019-07-03
MA46038B1 (fr) 2021-05-31
MX2019002129A (es) 2019-06-20
HRP20210621T1 (hr) 2021-05-28
PT3504210T (pt) 2021-04-19
WO2018041763A1 (en) 2018-03-08
IL293475B1 (en) 2024-06-01
TW201819382A (zh) 2018-06-01
MX383500B (es) 2025-03-14
DK3504210T3 (da) 2021-04-26
CR20190087A (es) 2019-04-30
PH12019500432B1 (en) 2023-03-24
BR112019003519A2 (pt) 2019-05-21
HUE053944T2 (hu) 2021-08-30
KR20220147702A (ko) 2022-11-03
SG10202010520SA (en) 2020-11-27
RU2019107957A3 (es) 2020-12-18
US10752630B2 (en) 2020-08-25
JP2022050632A (ja) 2022-03-30
MY197408A (en) 2023-06-16
KR102459155B1 (ko) 2022-10-28
RU2019107957A (ru) 2020-09-29
CL2019000512A1 (es) 2019-07-12
SI3504210T1 (sl) 2021-08-31
PL3504210T3 (pl) 2021-07-05
CA3034148A1 (en) 2018-03-08
SG11201901633WA (en) 2019-03-28
MA46038A (fr) 2019-07-03
IL284255A (en) 2021-07-29
AU2021204303A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
MX379474B (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
MX2020010949A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.
MX2023001876A (es) Derivados de rapamicina.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
ECSP16016726A (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
DOP2017000034A (es) Compuestos de imidazopiridazina
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
ECSP16083017A (es) Derivados de diheterociclo enlazado a cicloalquilo
CO2017003225A2 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos